Webinar: Treatment of amyloidosis: Current opinions and future outlook
View our expert-led webinar where past, current, and future therapeutic strategies for amyloidosis are presented
Review a timeline of therapeutic strategies for transthyretin-related familial amyloid polyneuropathy (TTR-FAP), ranging from liver transplantation to antibody therapy
View the clinical trial data investigating the long-term efficacy and safety of therapeutic strategies in TTR-FAP and hereditary transthyretin amyloidosis (hATTR) with polyneuropathy
▼ Tafamidis is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See https://yellowcard.mhra.gov.uk for how to report side effects.
This is a recording of our live webinar. This webinar recording has been chapterized to enable ease of viewing.
Register now to unlock the content
Register now to access the content on this page
Already registered?
If not, register below
MED-ALL-hATTR-2300002 | March 2023
Sign in or register to access exclusive content on this site
Register here to access the content on the site MED-ALL-CORP-2200029 | December 2022
You are now leaving MEDhub, a website provided by PTC Therapeutics. This link will take you to a website to which our Privacy Statement and our Terms and Conditions do not apply.
We encourage you to read the Privacy Policy and the Terms and Conditions of every website you visit. PTC Therapeutics does not endorse and/or influence the content found on websites not owned/operated by PTC Therapeutics.
The content you are trying to access is not currently available.
We will be updating the MEDhub site regularly to provide you with up-to-date, insightful expert-led content. To be notified when new additions become available, register now.